Financial Performance - The company's revenue for Q1 2023 was ¥951,417,159.09, representing a 7.04% increase compared to ¥888,836,734.49 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥394,728.53, a decline of 104.31% from a profit of ¥9,149,858.74 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 951,417,159.09, an increase of 7.06% compared to CNY 888,836,734.49 in the same period last year[21] - Operating profit for Q1 2023 decreased to CNY 7,304,228.83, down 59.5% from CNY 18,066,566.92 in the previous year[21] - The company reported a net loss attributable to shareholders of CNY 16,000,960.16, compared to a loss of CNY 15,606,231.63 in the previous year[19] - The net profit for Q1 2023 was -902,065.90 CNY, a significant decline compared to a net profit of 7,814,690.78 CNY in Q1 2022, representing a decrease of over 111%[22] - The company reported a total comprehensive income of -891,481.36 CNY for Q1 2023, compared to 7,815,211.37 CNY in Q1 2022, marking a decline of over 111%[22] Cash Flow and Investments - The net cash flow from operating activities was -¥221,509,803.49, a decrease of 410.50% compared to ¥71,339,618.63 in the same period last year[11] - The cash inflow from investment activities for Q1 2023 was 2,119,564,208.60 CNY, down from 6,080,578,426.29 CNY in Q1 2022, indicating a decrease of approximately 65%[25] - The cash outflow from investment activities was 1,760,902,169.05 CNY in Q1 2023, compared to 6,593,965,541.13 CNY in Q1 2022, reflecting a decrease of about 73%[25] - The net cash flow from financing activities for Q1 2023 was -110,972,152.16 CNY, compared to -22,104,128.34 CNY in Q1 2022, indicating a worsening situation[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,431,129,004.09, down 1.83% from ¥6,550,914,912.15 at the end of the previous year[5] - Total current assets decreased to CNY 4,761,788,679.00, down 2.5% from CNY 4,883,273,988.04 at the start of the year[19] - Total liabilities decreased to CNY 1,208,729,704.04, a reduction of 8.96% from CNY 1,327,624,130.74 at the beginning of the year[19] - Inventory increased to CNY 1,279,968,680.02, up 19.1% from CNY 1,074,458,576.25 at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 74,948[13] - Shanxi Zhendong Health Industry Group Co., Ltd. holds 29.41% of the shares, amounting to 302,230,191 shares[13] - The top ten shareholders include institutional investors and individuals, with the largest being Shanxi Zhendong Health Industry Group Co., Ltd.[13] - The total number of restricted shares held by executives is 3,436,410, with 75,000 shares released during the period[15] - The company reported a total of 51,364,735 shares held by Zhongtai Securities Asset Management, representing 5.00% of the shares[13] - The report indicates that 2,850,000 shares are held by individual shareholder Liu Yubin, with no restrictions[13] - The company has not disclosed any related party relationships among the top shareholders[13] Other Financial Metrics - The company's financial expenses decreased by 135.97% to -¥972,391.69, attributed to a reduction in bank borrowings compared to the previous year[10] - The fair value change income for the period was ¥3,953,915.30, reflecting a substantial increase of 1,326.34% compared to the previous year[10] - The company reported a significant increase in investment income, which rose by 182.19% to ¥9,782,844.63 due to higher financial management returns[10] - Research and development expenses for Q1 2023 were CNY 48,885,568.66, a decrease of 6.1% compared to CNY 51,888,172.00 in Q1 2022[21] - The basic and diluted earnings per share for Q1 2023 were both -0.0004 CNY, compared to 0.0089 CNY in Q1 2022, reflecting a significant decline[22] Reporting Period - The financial report for Q1 2023 is prepared as of March 31, 2023[17] - The report does not mention any new product developments or market expansion strategies[16]

Financial Performance - The company reported a significant decline in profitability due to the impact of national drug procurement policies, with major products like Bicalutamide capsules experiencing a year-on-year decrease in profitability [4]. - The company's operating revenue for 2022 was ¥3,728,555,341.19, a decrease of 26.80% compared to ¥5,093,776,334.20 in 2021 [26]. - The net profit attributable to shareholders was -¥51,290,041.06 in 2022, representing a decline of 101.96% from ¥2,617,429,564.94 in 2021 [26]. - The net cash flow from operating activities decreased by 69.66% to ¥86,308,195.25 in 2022, down from ¥284,449,199.18 in 2021 [26]. - The total assets at the end of 2022 were ¥6,550,914,912.15, a reduction of 35.10% from ¥10,093,441,565.87 at the end of 2021 [26]. - The company's basic earnings per share for 2022 was -¥0.0499, compared to ¥2.5474 in 2021, marking a decline of 101.96% [26]. - The weighted average return on equity was -0.80% in 2022, down from 38.01% in 2021, a decrease of 38.81% [26]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, which was -¥148,433,723.12 in 2022 compared to ¥133,863,713.40 in 2021, a decline of 210.88% [26]. - The company received government subsidies amounting to ¥23,064,361.28 in 2022, down from ¥67,764,860.92 in 2021 [33]. Research and Development - R&D expenses increased from 4.29% to 4.78% of operating revenue, reflecting the company's commitment to enhancing its core competitiveness through brand building and product development [4]. - The company has over 130 R&D projects and has undertaken more than 50 national and provincial-level projects, focusing on innovative drugs, generic drugs, and modern traditional Chinese medicine [61]. - The company is focusing on developing products with cost advantages in less competitive therapeutic areas, which may provide good opportunities [40]. - The company has initiated a strategy to expand its OTC product matrix and enhance its e-commerce operations, focusing on dermatological products for high-quality development [67]. - The company has established a risk management mechanism for R&D projects, including regular evaluations by an expert committee [141]. - R&D investment in 2022 amounted to ¥202.66 million, representing 5.44% of operating revenue, an increase from 5.07% in 2021 and 3.77% in 2020 [95]. Market Position and Strategy - The pharmaceutical industry in which the company operates is experiencing favorable conditions, with no signs of overcapacity or technological obsolescence [4]. - The pharmaceutical industry is shifting focus from generic drugs to innovative drugs, indicating a strategic pivot for future growth opportunities [39]. - The company is engaged in the R&D, production, and sales of generic and innovative drugs across various therapeutic areas, including oncology and dermatology [43]. - The company has established a professional sales team and a marketing management model, covering 23 provinces, 5 autonomous regions, and 4 municipalities directly under the central government [47]. - The company has developed an online sales model in collaboration with major platforms like Alibaba, JD.com, and Pinduoduo [50]. - The company is focusing on long-term brand development for products like Dafeixin Minoxidil lotion, which may pressure short-term performance but is expected to enhance competitiveness [4]. Governance and Management - The company maintains independence from its controlling shareholder, ensuring autonomous decision-making in operations [149]. - The company has a structured performance evaluation and incentive mechanism for its board members and senior management [152]. - The company actively engages with stakeholders to balance interests and enhance governance transparency [155]. - The company adheres to legal requirements for corporate governance, ensuring compliance with relevant regulations [147]. - The company reported a total of 2,316,272 shares held by the chairman, with no changes during the reporting period [160]. - The independent director positions were filled by individuals with terms ending in August 2024, indicating stability in governance [160]. Future Outlook - The company has set a future outlook with a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20% [173]. - Strategic acquisitions are planned, with a budget of 500 million RMB allocated for potential mergers and acquisitions to enhance product offerings [173]. - The company is investing in new technology research, with a budget of 100 million RMB dedicated to developing advanced drug delivery systems [173]. - The company aims to improve R&D efficiency through collaboration, focusing on innovative drug development and enhancing project management [135]. - The company is committed to expanding its market presence and enhancing its product offerings through strategic initiatives [178]. Employee and Training Initiatives - The company has implemented a training program with a focus on employee development, requiring each employee to complete no less than 120 hours of training annually [196]. - The employee stock ownership plan included 1,759 core employees holding a total of 20,167,608 shares, representing 1.96% of the company's total equity [200]. - The company emphasizes a comprehensive training system with 14 departments and 58 specialties to cultivate skilled talent [196]. - The company has adjusted its salary system to a "three-tier nine-level" structure, enhancing personnel assessment and salary adjustment mechanisms [194]. - The total number of employees at the end of the reporting period was 3,693, with 1,887 in sales, 1,104 in production, and 335 in technical roles [193].

证券代码：300158 证券简称：振东制药 公告编号：2023-024 为做好中小投资者保护工作，增进投资者对公司的了解和认同， 以提升公司治理水平和企业整体价值，现就公司 2022 年度网上业绩 说明会提前向投资者征集相关问题。投资者可于 2023 年 5 月 5 日前 登录网址（https://s.comein.cn/ANK5y）或扫描以下参会二维码进行会 前提问，公司将在 2022 年度网上业绩说明会上，对投资者普遍关注 的问题进行回答。 出席本次年度网上业绩说明会的人员包括：公司董事长李安平先 生、公司独立董事武滨先生、公司总经理杨连民先生、公司财务总监 刘长禄先生和董事会秘书周红军先生。 山西振东制药股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为了使投资者能够进一步了解公司的生产经营情况，公司拟安排 于 2023 年 5 月 5 日（星期五）15:00～17:00，在"进门财经"举办 2022 年度网上业绩说明会。 投资者可以通过登录网址（https://s.comein.cn/ANK5 ...

Group 1: Company Overview - The main product of Shanxi Zhendong Pharmaceutical Co., Ltd. is primarily for internal use, with a small portion sold externally, mainly through direct contact with manufacturers, rather than through the herbal market [2] - The company is exploring the U.S. market for its traditional Chinese medicine products, as there are approximately 6,000 TCM research institutions in the U.S., with around 4,000 requiring imports of Chinese extracts [2] Group 2: Product Development and Sales - The company aims to diversify its product line beyond its main product, Yanshu, which has limited usage; it plans to increase investment in secondary products like Bicalutamide and Pemetrexed Disodium to drive growth [3] - Currently, the company has over 1,000 sales personnel, focusing on self-sales of core products [3] Group 3: Mergers and Acquisitions - The company is actively seeking suitable merger and acquisition targets, having established a new investment team to identify quality opportunities [3] Group 4: International Collaboration - The company has established a research office in collaboration with the National Academy of Traditional Chinese Medicine at the U.S. National Cancer Institute to promote TCM in cancer treatment [4] - It is a member of the International TCM Cancer Treatment Alliance, aiming to accelerate research and promotion of traditional Chinese medicine [4] - The company signed a cooperation agreement for EU registration of its compound TCM products, marking its entry into the European market [4] Group 5: Research Achievements - Recent research by the company, in collaboration with the Guang'anmen Hospital of the China Academy of Chinese Medical Sciences and the U.S. National Cancer Institute, has demonstrated the efficacy of its compound Ku Shen injection in treating cancer pain, published in a prominent international oncology journal [5] - The Yanshu compound Ku Shen injection is effective in inhibiting cancer pain, bleeding, and tumor growth, and is widely used in cancer treatment [5]

Group 1: Major Asset Restructuring - The purpose of the major asset restructuring is to enhance the company's core competitiveness by acquiring products with strong market presence, such as Calcium D3 tablets and granules, which have high market recognition and share [3] - The acquisition will allow the company to quickly gain access to competitive products, diversify its product range, and reduce operational risks [3] - The integration of Calcium D3 products with existing offerings aims to boost sales of other OTC products, leveraging the growing health product market [3] Group 2: Impact on Business Strategy - Post-restructuring, the company will have a richer product line and gain access to competitive pharmaceutical varieties, facilitating rapid growth [3] - The acquired company, Kangyuan Pharmaceutical, will become a wholly-owned subsidiary, benefiting from improved governance and management through capital market support [4] - The transaction aligns with both parties' strategic goals, maximizing profits and achieving strategic synergy [4] Group 3: Dividend and Profit Distribution - The board will consider investors' reasonable demands for returns, discussing profit distribution plans, including stock dividend proposals, based on business development and financial needs [4] - Any progress on profit distribution will be announced in accordance with regulations [4] Group 4: Sales and Market Performance - The sales volume of the company's main product, Yanshu Injection, is expected to remain stable this year, with ongoing clinical trials for new formulations [5] - The company aims to strengthen its sales team as a key strategy for future growth, addressing past mismatches in brand, capacity, and marketing [6] - The company has implemented significant reforms in its marketing structure, relocating its marketing team to Beijing to enhance talent acquisition and information flow [6] Group 5: Future Development Plans - The company plans to continue investing in traditional Chinese medicine and improve its supply chain to support farmers, with significant benefits already observed [5] - The focus remains on developing traditional Chinese medicine oncology drugs, with a clear strategy for future research and development [6]

证券代码：300158 证券简称：振东制药 编号：2 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------| | | | | | | | □特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 √路演活动 | | 类别 | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称及 | 广大投资者 | | | 人员姓名 | | | | 时间 | 2016 年 1 月 29 | 日 | | 地点 | 上海世纪大道 | 1568 号中建大厦 22F 中信证券 04 会议室 | | 上市公司接待人 员姓名 | 李安平 宁潞宏 | 马士锋 徐根旺 | | 投资者关系活动 | 1 . | 复方苦参注射液现在能否完全满足企业生产需求？ | | 主要内容介绍 | | 答：现在完全能满足生产需求，岩舒是我们的独家产品，有 | | | G ...

证券代码：300158 证券简称：振东制药 编号：2020-001 山西振东制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------|--------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 √路演活动 | | | 类别 | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称及 | 机会宝 范莉莉 | | | 人员姓名 | 机会宝 客服 | | | | 机会宝 雷晨昊 | | | | 机会宝 彭博 | | | | 机会宝 王冰清 | | | | 机会宝 王戊军 | | | | 机会宝 吴琪 | | | | 机会宝 肖佳楣 | | | | 机会宝 徐姗姗 | | | | 机会宝 益正徐翾 | | | | 机会宝 张佳 | | | | 中银基金 王帅 | | | | 中投证券 袁超 | | | --- | --- ...

证券代码：300158 证券简称：振东制药 山西振东制药股份有限公司投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | --- | |----------------|--------------|--------------------------------|-------|-------| | | | | | | | | 特定对象调研 | 分析师会议 | | | | | 媒体采访 | 业绩说明会 | | | | 投资者关系活动 | 新闻发布会 | 路演活动 | | | | 类别 | 现场参观 | | | | | | | 其他（请文字说明其他活动内容） | | | | | 贵源投资 | 赖正健 | | | | | 贵源投资 | 纵华雷 | | | | | 巴富罗投资 | 浩 | | | | | 移 民 局 | 费维俊 | | | | | 中银证券 | 魏泽辉 | | | | | 中银证券 | 徐东栋 | | | | 参与单位名称及 | 承风金平 | 承 | | | | 人员姓名 | 证券日报 | 陈慕鸿 | | | | | 证券日报 | 赵瑞东 | | | | ...

证券代码：300158 证券简称：振东制药 山西振东制药股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | --- | |----------------|---------------------|--------------|--------------------------------|-------| | | | | | | | | | 特定对象调研 | 分析师会议 | | | | 媒体采访 | | 业绩说明会 | | | 投资者关系活动 | | 新闻发布会 | 路演活动 | | | 类别 | | | | | | | 现场参观 | | | | | | | | 其他（请文字说明其他活动内容） | | | | 浦银安盛： | | | | | | 研究总监 | | 蒋佳良 | | | 参与单位名称及 | 基金经理 基金经理 | 赵 | 胡攸乔 宁 | | | 人员姓名 | 基金经理 | | 杨富麟 | | | | 研 究 员 | | 杨达伟 | | | | 研 究 员 | 徐 | 博 | | | | 研 究 员 | 沈 | 瑞 | | | 时间 | ...

证券代码：300158 证券简称：振东制药 山西振东制药股份有限公司投资者关系活动记录表 编号：2021-006 | --- | --- | --- | --- | --- | |----------------|--------------|--------------------------------|-------|-------| | | | | | | | | 特定对象调研 | 分析师会议 | | | | | 媒体采访 | 业绩说明会 | | | | 投资者关系活动 | 新闻发布会 | 路演活动 | | | | 类别 | 现场参观 | | | | | | | 其他（请文字说明其他活动内容） | | | | | 华泰证券 | 岳梅梅 | | | | | 华泰证券 | 李奕玮 | | | | | 华泰证券 | 张光耀 | | | | | 泾溪投资 | 宇 | | | | | 中信资管 | 康 | | | | | 北信瑞丰 | 庞文杰 | | | | | 嘉实基金 | 朱子君 | | | | | 嘉实基金 | 歌 | | | | | 嘉实基金 | 肖琪严 | | | | 参与单位名称及 | 嘉实基金 | ...